Big Pharma Split Corp Class A Asset Resilience Ratio
Big Pharma Split Corp Class A asset resilience ratio. Big Pharma Split Corp Class A (PRM) has an Asset Resilience Ratio of 93.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Big Pharma Split Corp Class A (PRM) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Big Pharma Split Corp Class A (2017–2025)
Asset resilience ratio of Big Pharma Split Corp Class A from 2017 to 2025. This chart shows how Big Pharma Split Corp Class A's Asset Resilience Ratio has changed over time. Read Big Pharma Split Corp Class A (PRM) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Big Pharma Split Corp Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Big Pharma Split Corp Class A's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$29.87 Million | 93.81% |
| Total Liquid Assets | CA$29.87 Million | 93.81% |
Asset Resilience Insights
- Very High Liquidity: Big Pharma Split Corp Class A maintains exceptional liquid asset reserves at 93.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Big Pharma Split Corp Class A Industry Peers by Asset Resilience Ratio
Compare Big Pharma Split Corp Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Bajaj Holdings & Investment Limited
NSE:BAJAJHLDNG |
Asset Management | 1.12% |
|
IGM Financial Inc.
TO:IGM |
Asset Management | 12.70% |
|
Groep Brussel Lambert NV
BR:GBLB |
Asset Management | 3.60% |
|
Sprott Physical Gold and Silver Trust
TO:CEF |
Asset Management | 99.66% |
|
Australian Foundation Investment Company Ltd
AU:AFI |
Asset Management | 0.01% |
|
Golub Capital BDC Inc
NASDAQ:GBDC |
Asset Management | -96.41% |
|
CI Financial Corp
TO:CIX |
Asset Management | 1.81% |
|
Australian United Investment Company Ltd
AU:AUI |
Asset Management | 0.01% |
Big Pharma Split Corp Class A Asset Resilience Ratio by Year (2017–2025)
Big Pharma Split Corp Class A asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Big Pharma Split Corp Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 93.81% | CA$29.87 Million ≈ $21.61 Million |
CA$31.84 Million ≈ $23.03 Million |
-1.91pp |
| 2024-12-31 | 95.71% | CA$25.17 Million ≈ $18.21 Million |
CA$26.30 Million ≈ $19.03 Million |
+93.01pp |
| 2023-12-31 | 2.71% | CA$718.24K ≈ $519.56K |
CA$26.53 Million ≈ $19.19 Million |
-57.98pp |
| 2022-12-31 | 60.69% | CA$23.73 Million ≈ $17.16 Million |
CA$39.10 Million ≈ $28.28 Million |
-32.71pp |
| 2021-12-31 | 93.40% | CA$35.32 Million ≈ $25.55 Million |
CA$37.81 Million ≈ $27.35 Million |
-4.29pp |
| 2020-12-31 | 97.69% | CA$22.40 Million ≈ $16.21 Million |
CA$22.93 Million ≈ $16.59 Million |
+0.80pp |
| 2019-12-31 | 96.89% | CA$26.33 Million ≈ $19.05 Million |
CA$27.18 Million ≈ $19.66 Million |
-1.66pp |
| 2018-12-31 | 98.55% | CA$33.14 Million ≈ $23.98 Million |
CA$33.63 Million ≈ $24.33 Million |
+5.66pp |
| 2017-12-31 | 92.89% | CA$30.18 Million ≈ $21.83 Million |
CA$32.49 Million ≈ $23.50 Million |
-- |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.